补肺活血胶囊联合2HRZE/4HR方案治疗肺结核的临床疗效
|
摘要
目的:观察补肺活血胶囊联合2HRZE/4HR方案治疗肺结核的临床疗效。方法:选取82例肺结核患者为研究对象,按随机数字表法将其分为对照组和观察组,每组41例。对照组采用2HRZE/4HR方案治疗,观察组在对照组的基础上联合补肺活血胶囊治疗,两组均持续治疗4个月。比较两组临床疗效,治疗前后CD8~+、CD4~+、CD4~+/CD8~+水平,临床症状(发热、咳嗽、盗汗、消瘦)评分及不良反应发生情况。结果:观察组的治疗有效率为90.24%(37/41),高于对照组的70.73%(29/41),差异有统计学意义(P<0.05);治疗后观察组血清CD8~+水平低于对照组,CD4~+、CD4~+/CD8~+水平高于对照组,差异均有统计学意义(P<0.05);治疗后观察组发热、咳嗽、盗汗、消瘦评分均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:补肺活血胶囊联合2HRZE/4HR方案治疗肺结核患者的效果优于单纯2HRZE/4HR方案治疗。
Objective: To observe clinical efficacy of Bufei Huoxue capsules combined with 2 HRZE/4 HR regimen in treatment of pulmonary tuberculosis. Methods: 82 patients with pulmonary tuberculosis were selected as the study subjects, and they were divided into control group(n=41) and observation group(n=41) according to the random number table method. The control group was treated with 2 HRZE/4 HR regimen, while the observation group was treated with Bufei Huoxue capsules on the basis of that of the control group. Both groups were treated for 4 months. The clinical efficacies of the two groups were compared. Further, the levels of CD8~+, CD4~+, CD4~+/CD8~+, the clinical symptom scores(fever, cough, night sweat, weight loss) and adverse reactions were compared before and after the treatment. Results: The effective rate in the observation group was 90.24%(37/41), which was significantly higher than that in the control group(70.73%, 29/41), and the difference was statistically significant(P<0.05). After the treatment, the serum CD8~+ level in the observation group was significantly lower than that in the control group, the levels of CD4~+ and CD4~+/CD8~+ were significantly higher than those in the control group, and the differences were statistically significant(P<0.05). After the treatment, the fever, cough, night sweat and weight loss scores in the observation group were significantly lower than those in the control group, and the differences were statistically significant(P<0.05). Further, there were no statistical differences in the adverse reaction incidence between the two groups(P>0.05). Conclusions: Bufei Huoxue capsules combined with 2 HRZE/4 HR regimen in the treatment of pulmonary tuberculosis is superior to single 2 HRZE/4 HR regimen.
Objective: To observe clinical efficacy of Bufei Huoxue capsules combined with 2 HRZE/4 HR regimen in treatment of pulmonary tuberculosis. Methods: 82 patients with pulmonary tuberculosis were selected as the study subjects, and they were divided into control group(n=41) and observation group(n=41) according to the random number table method. The control group was treated with 2 HRZE/4 HR regimen, while the observation group was treated with Bufei Huoxue capsules on the basis of that of the control group. Both groups were treated for 4 months. The clinical efficacies of the two groups were compared. Further, the levels of CD8~+, CD4~+, CD4~+/CD8~+, the clinical symptom scores(fever, cough, night sweat, weight loss) and adverse reactions were compared before and after the treatment. Results: The effective rate in the observation group was 90.24%(37/41), which was significantly higher than that in the control group(70.73%, 29/41), and the difference was statistically significant(P<0.05). After the treatment, the serum CD8~+ level in the observation group was significantly lower than that in the control group, the levels of CD4~+ and CD4~+/CD8~+ were significantly higher than those in the control group, and the differences were statistically significant(P<0.05). After the treatment, the fever, cough, night sweat and weight loss scores in the observation group were significantly lower than those in the control group, and the differences were statistically significant(P<0.05). Further, there were no statistical differences in the adverse reaction incidence between the two groups(P>0.05). Conclusions: Bufei Huoxue capsules combined with 2 HRZE/4 HR regimen in the treatment of pulmonary tuberculosis is superior to single 2 HRZE/4 HR regimen.
引文
[1]杜姗菱,李春燕,欧万秋,等.肺结核患者营养状况的针对性护理研究[J].重庆医学,2015,44(27):3883-3884.
[2]何秀丽.贞芪扶正胶囊联合抗结核药治疗肺结核疗效观察[J].内蒙古中医药,2014,33(34):16-17.
[3]龚年金.左氧氟沙星及胸腺肽联合2HRZE/4HR方案治疗初治肺结核的临床疗效及对痰上清液细胞因子水平的影响[J].实用心脑肺血管病杂志,2016,24(7):117-120.
[4]中华医学会结核病学分会.肺结核诊断和治疗指南[J].中国实用乡村医生杂志,2013,20(2):7-11.
[5]徐红艳.参麦注射液对肺结核患者血清β-CAR、IL-17及CD4+细胞表达的影响[J].世界中医药,2018,13(1):119-123.
[6]黄舒然,葛海波.2HRZE/4HR方案联合加味葶苈大枣泻肺汤对肺结核患者疗效及免疫力的影响[J].吉林中医药,2018,38(7):786-789.
[7]陈勇毅,阮运河,戴芬.结核丸联合2HRZE/4HR方案治疗初患涂阳肺结核随机平行对照研究[J].实用中医内科杂志,2017,31(7):52-54.
[8]王姬,郑雁,周建芳,等.初治涂阳肺结核患者肺泰胶囊联合2HRZE/4HR化疗疗效观察[J].预防医学,2017,29(7):708-710.
[9]马治刚,余洁,黎怡,等.补肺活血胶囊对支气管哮喘缓解期患者炎性因子及免疫功能的影响[J].检验医学与临床,2016,13(19):2746-2748.
[10]杨铭,袁平,吴怀戈,等.肺结核患者外周血T淋巴细胞亚群检测结果与病情的相关性研究[J].中国防痨杂志,2017,39(10):1093-1099.
[2]何秀丽.贞芪扶正胶囊联合抗结核药治疗肺结核疗效观察[J].内蒙古中医药,2014,33(34):16-17.
[3]龚年金.左氧氟沙星及胸腺肽联合2HRZE/4HR方案治疗初治肺结核的临床疗效及对痰上清液细胞因子水平的影响[J].实用心脑肺血管病杂志,2016,24(7):117-120.
[4]中华医学会结核病学分会.肺结核诊断和治疗指南[J].中国实用乡村医生杂志,2013,20(2):7-11.
[5]徐红艳.参麦注射液对肺结核患者血清β-CAR、IL-17及CD4+细胞表达的影响[J].世界中医药,2018,13(1):119-123.
[6]黄舒然,葛海波.2HRZE/4HR方案联合加味葶苈大枣泻肺汤对肺结核患者疗效及免疫力的影响[J].吉林中医药,2018,38(7):786-789.
[7]陈勇毅,阮运河,戴芬.结核丸联合2HRZE/4HR方案治疗初患涂阳肺结核随机平行对照研究[J].实用中医内科杂志,2017,31(7):52-54.
[8]王姬,郑雁,周建芳,等.初治涂阳肺结核患者肺泰胶囊联合2HRZE/4HR化疗疗效观察[J].预防医学,2017,29(7):708-710.
[9]马治刚,余洁,黎怡,等.补肺活血胶囊对支气管哮喘缓解期患者炎性因子及免疫功能的影响[J].检验医学与临床,2016,13(19):2746-2748.
[10]杨铭,袁平,吴怀戈,等.肺结核患者外周血T淋巴细胞亚群检测结果与病情的相关性研究[J].中国防痨杂志,2017,39(10):1093-1099.